If you are curious about investing in Life Sciences but don't know much about it, our Life Sciences Investor Briefing may be for you. Or if you are already invested, this is an ideal opportunity to catch up with the sector.
London South East have partnered with Hardman & Co who have an expertise in the Life Sciences and Biotech fields, and we were joined on the evening of 11 September by the CEO of Destiny Pharma, the CFO of Shield Therapeutics and the CEO of Open Orphan, all AIM-listed companies. The evening was kicked off by Dr Martin Hall who heads the Hardman Life Sciences team and he puts the sector in context for us.
This webcast is an 'as-live' record of the event and includes the Q&A after each presentation.
Our speakers were:
1. Dr Martin Hall, Head of Life Sciences, Hardman & Co 6:51
2. Neil Clark, CEO, Destiny Pharma 36:32
3. Tim Watts, CFO, Shield Therapeutics 1:01:16
4. Cathal Friel, CEO, Open Orphan 01:29:42
